[{"command":"settings","settings":{"pluralDelimiter":"\u0003","suppressDeprecationErrors":true,"ajaxPageState":{"libraries":"eJxFytEKgCAMRuEXMn2k-GsrB9PG0nr9IMIuz8fh5bKmlKRewnfgLwuTYJKCnYcZHLvD8lQOgs4rnMI7pk20sccV1uSoYZxnIu8Gjb_EXq0vKmdmegDh4DCV","theme":"ebvptld","theme_token":null},"ajaxTrustedUrl":[],"user":{"uid":0,"permissionsHash":"4867837929d82f46a0b8d631cb1b853ab572e5989466da9ff30f538d13a4af8e"}},"merge":true},{"command":"add_css","data":[{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_zFE0GntIr5sJtoaw0onuR1rz-A25LT_DlBnsJ-mCx8I.css?delta=0\u0026language=en\u0026theme=ebvptld\u0026include=eJxFykEOgCAMBMAPITzJLLRKkwJNAd_vTa-T4fzYUkoGx-2werRB0LPAKTQmQbpEF3sssCWjh2_ORL4NGn-Ju9vOKrMyvTgpIzs"},{"rel":"stylesheet","media":"all","href":"\/sites\/default\/files\/css\/css_rp-nJs0EOjtUdAxu7hbmuIO3NIwEYbwhfB4JNT82dPg.css?delta=1\u0026language=en\u0026theme=ebvptld\u0026include=eJxFykEOgCAMBMAPITzJLLRKkwJNAd_vTa-T4fzYUkoGx-2werRB0LPAKTQmQbpEF3sssCWjh2_ORL4NGn-Ju9vOKrMyvTgpIzs"}]},{"command":"add_js","selector":"body","data":[{"src":"\/sites\/default\/files\/js\/js_fgI_F9T9iHdlscNdB1Tqblhfn81ETkj65lf7riv4k8o.js?scope=footer\u0026delta=0\u0026language=en\u0026theme=ebvptld\u0026include=eJxLzi9K1U8pKi1IzNFLyUzMyU_XS8xKrNBJTSorKMlJ0c_MK8tMLYdzyyuLM8sr0wE6xBUe"}]},{"command":"openDialog","selector":"#drupal-modal","settings":null,"data":"\n  \u003Cdiv id=\u0022p243\u0022 class=\u0022js-inview paragraph paragraph--type--modal-card paragraph--view-mode--teaser modal wysiwyg\u0022\u003E\n         \n  \u003Ch3\u003E\u003Cstrong\u003EPTLD-1 RSST STUDY\u003Csup\u003E18\u003C\/sup\u003E\u003C\/strong\u003E\u003C\/h3\u003E\n\u003Cp\u003E\u003Cspan class=\u0022regular\u0022\u003E\u003Cstrong\u003EResponse-adapted sequential treatment\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022regular\u0022\u003EThe subsequent Phase 2 PTLD-1 RSST trial evaluated a response-adapted strategy after rituximab induction, showing that rituximab consolidation in patients achieving CR was safe and effective.\u003C\/span\u003E\u003C\/p\u003E\n\u003Cdiv class=\u0022row rsstStudy\u0022 style=\u0022margin:0 -1.2rem;\u0022\u003E\n\u003Cdiv class=\u0022col-md-12 primary-endpoint\u0022 style=\u0022padding:1.2rem;\u0022\u003E\n\u003Cp\u003E\u003Cstrong\u003EPrimary endpoint results\u003C\/strong\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022edd1871c248ef65ba400883bec898fa51\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EORR: 88% (95% CI, 81\u201393%)\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022eef684fd69e91c6718c065b729c0073b5\u0022\u003E\u003Cspan class=\u0022small\u0022\u003ECR: 70% (95% CI, 61\u201377%)\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e05b3b54a5e878ce99dccf758296e74a4\u0022\u003E\u003Cspan class=\u0022small\u0022\u003E3-year response duration: 82% (95% CI, 74\u201390%)\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cstrong\u003EProgression-free\u0026nbsp;\u003C\/strong\u003E\u003Cbr\u003E\u003Cstrong\u003Eat 3 years in the low-risk group\u003C\/strong\u003E\u003C\/p\u003E\n\u003Cdiv class=\u0022row\u0022 style=\u0022margin:0 -1.2rem;\u0022\u003E\n\u003Cdiv class=\u0022flex rsst-pies\u0022\u003E\n\u003Cdiv class=\u0022rsst-pie progressFree\u0022 style=\u0022margin-right:1%;\u0022\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-rsst-89%25.png?itok=biOGP2_I\u0022 width=\u0022600\u0022 height=\u0022600\u0022 alt=\u002289%\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003EResponse-adapted\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003Esequential treatment\u0026nbsp;(8R)\u003C\/strong\u003E\u0026nbsp;\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003En=37\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022rsst-pie progressFree\u0022 style=\u0022margin-left:1%;\u0022\u003E\n\u003Cdiv\u003E\n  \n  \n    \u003Cimg src=\u0022\/sites\/default\/files\/styles\/rte\/public\/2026-02\/study1-rsst-69%25.png?itok=HdIMcfn3\u0022 width=\u0022600\u0022 height=\u0022600\u0022 alt=\u002269%\u0022 loading=\u0022lazy\u0022\u003E\n\n\n\n\n\u003C\/div\u003E\n\u003Cp class=\u0022text-align-center\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003ESequential treatment\u0026nbsp;\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003E(4R-4CHOP)\u003C\/strong\u003E\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022smallish\u0022\u003En=14\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\u003Cp\u003E\u003Cbr\u003E\u003Cbr\u003E\u003Cspan class=\u0022small\u0022\u003EAdapted from Trappe R, et al. Journal of Clinical Oncology. 2017.\u003C\/span\u003E\u003C\/p\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\u003Cdiv class=\u0022col-md-12 primary-endpoint\u0022 style=\u0022padding:1.2rem;\u0022\u003E\n\u003Cp\u003E\u003Cstrong\u003EImproved 3-year TTP with rituximab\u0026nbsp;\u003C\/strong\u003E\u003Cbr\u003E\u003Cstrong\u003Econsolidation vs PTLD-1 ST\u003C\/strong\u003E\u003C\/p\u003E\n\u003Cp\u003E\u003Cspan class=\u0022smallish\u0022\u003EAt 3 years, TTP was improved in the low-risk rituximab consolidation group* vs the PTLD-1 ST cohort who achieved CR after rituximab induction and continued ST with CHOP.\u003C\/span\u003E\u003C\/p\u003E\n\u003Cp\u003E\u003Cspan class=\u0022small\u0022\u003E*Patients with CR at interim staging in the low-risk group (RSST cohort).\u003C\/span\u003E\u003C\/p\u003E\n\u003Cp id=\u0022progressFreeStudyDesign\u0022\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003EStudy design\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022efd38747738eecb0ca3013174ec37d1d1\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EProspective, international, multicentre, phase 2 trial\u0026nbsp;\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ecf9c2231249316faf0a24114b47da3c2\u0022\u003E\u003Cspan class=\u0022small\u0022\u003E152 treatment-naive adult SOT recipients with CD20-positive PTLD unresponsive to RIS\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ecd9180013a43b2146d3fc9ce4a874cfc\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EInduction: four weekly doses of rituximab\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ea64941c6a997d7bf05872b00df51df49\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EComplete responders continued with four courses of rituximab every\u0026nbsp;\u003C\/span\u003E\u003Cbr\u003E\u003Cspan class=\u0022small\u0022\u003E21 days\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e3312c97cd1c6110ae4428a7c904453bd\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EAll others received four courses of rituximab + CHOP every 21 days\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022ea9a81b5bdea6171db9df32a21082ad64\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EPrimary endpoint: treatment efficacy, assessed by response rate in patients who completed therapy, and response duration in those who completed therapy and responded\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003Cp\u003E\u003Cspan class=\u0022smallish\u0022\u003E\u003Cstrong\u003EAdverse events\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\n\u003Cul\u003E\n\u003Cli data-list-item-id=\u0022e21d1d0ab093c616e9c78b59d09bcdd9d\u0022\u003E\u003Cspan class=\u0022small\u0022\u003EGrade 3\/4 infections occurred in 34% of patients\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e5ec55ec52ec6dc3ef39b7101663bc27d\u0022\u003E\u003Cspan class=\u0022small\u0022\u003E63% experienced Grade 3\/4 leukopenia\u003C\/span\u003E\u003C\/li\u003E\n\u003Cli data-list-item-id=\u0022e115bee933ce2a509521ae2bb6d9eab9b\u0022\u003E\u003Cspan class=\u0022small\u0022\u003ETreatment-related mortality was 8%\u003C\/span\u003E\u003C\/li\u003E\n\u003C\/ul\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\n\n\n      \u003C\/div\u003E\n","dialogOptions":{"width":"60%","modal":true,"title":""}}]